Table 4.
Bivariate and multivariate, multinomial logistic regression of clinical and treatment-related factors associated with molecular response
| Variable | Molecular response, n (%) | Crude OR (95% CI) | Adjusted OR (95% CI) | ||||
|---|---|---|---|---|---|---|---|
| Failure, n = 104 (65.8) | Warning, n = 17 (10.8) | Optimal, n = 37 (23.4) | Warning vs optimal | Failure vs optimal | Warning vs optimal | Failure vs optimal | |
| Abdominal fullness | |||||||
| Present | 92 (67.6) | 16 (11.8) | 28 (20.6) | 5.14 (0.60- 44.4) | 2.46 (0.94-6.45) | — | — |
| Not present | 12 (54.6) | 1 (4.5) | 9 (40.9) | 1.00 | 1.00 | — | — |
| Previous BT | |||||||
| Yes | 41 (78.9) | 5 (9.6) | 6 (11.5) | 2.11 (0.55- 8.40) | 3.36 (1.29-8.77) | 2.11 (0.54- 8.25) | 3.48 (1.32-9.17) |
| No | 63 (59.4) | 12 (11.3) | 31 (29.3) | 1.00 | 1.00 | 1.00 | 1.00 |
| Sokal risk groups | |||||||
| High | 32 (74.4) | 3 (7.0) | 8 (18.6) | 9.2 × 105 (0,–) | 2.67 (0.60-11.7) | — | — |
| Intermediate | 35 (68.6) | 6 (11.8) | 10 (19.6) | 1.4 × 106 (0,–) | 2.33 (0.55-9.92) | — | — |
| Low | 6 (60.0) | 0 (0.0) | 4 (40.0) | 1.00 | 1.00 | — | — |
| Cytopenia from imatinib | |||||||
| Present | 70 (74.5) | 6 (6.4) | 18 (19.1) | 0.58 (0.18-1.88) | 2.17 (1.01-4.66) | 0.59 (0.18-1.93) | 2.26 (1.03-4.96) |
| Not present | 34 (53.1) | 11 (17.2) | 19 (29.7) | 1.00 | 1.00 | 1.00 | 1.00 |
| Adherence | |||||||
| High | 24 (60.0) | 5 (12.5) | 11 (27.5) | 0.84 (0.21-3.43) | 0.59 (0.23-1.51) | — | — |
| Medium | 32 (64.0) | 5 (10.0) | 13 (26.0) | 0.71 (0.18-2.84) | 0.67 (0.27-1.62) | — | — |
| Low | 48 (70.6) | 7 (10.3) | 13 (19.1) | 1.00 | 1.00 | — | — |
Data in column headings are the percentages of the total group of 158 patients. Data in the table body are number of patients (percentage of the response category). Bold statistics have P < .05.
BT, blood transfusion.